2004 News Archive
New Sales and Marketing Director for Europe appointed
15 December 2004
Protherics PLC (Protherics), the international biopharmaceuticals company, is pleased to announce the appointment of David Briscoe as Director of Sales and Marketing, Europe.
Protherics PLC Interim Results
07 December 2004
Protherics PLC, the international biopharmaceutical company, today announces its interim results for the six months to 30 September 2004.
Protherics Analyst Presentation
07 December 2004
Presentation given to Analysts on Tuesday 7th December.
Application made to UK Listing Authority
29 October 2004
Application has been made to the UK Listing Authority and to the London Stock Exchange for admission to the Official List of 200,040 ordinary shares of 2p each in the Company.
Notification of Interim Results
23 October 2004
London, 22 October, 2004, Protherics plc, the international biopharmaceutical company, will announce its interim results for the six months ended 30th September 2004, on Tuesday 07 December 2004.
Protherics Plc review of early stage portfolio
22 September 2004
Protherics Plc (“Protherics”), the international biopharmaceuticals company, today announces the transfer of the former Enact Pharma plc (“Enact”) R&D function at Porton Down and the out-licensing and assignment of certain non-core intellectual property (“IP”), including know-how and patents, to two UK start-up companies.
Appointment of Vice President Sales and Marketing US
22 September 2004
Protherics PLC ("Protherics") the international biopharmaceuticals company, is pleased to announce that it has appointed Joyce Emerson Cleary as Vice President, Sales and Marketing, Protherics Inc. in the US.
Protherics Files DigiFab Marketing Application in the UK
03 September 2004
Protherics PLC ("Protherics") the international biopharmaceutical company, announces the submission of its marketing authorisation application ("MAA") for DigiFab to the Medicines and Healthcare products Regulatory Agency ("MHRA") in the UK.
Director~s Dealings
25 August 2004
Protherics PLC ("the Company") announces the take-up by Directors of their entitlements to new Ordinary Shares of 2p each in the capital of the Company ("Ordinary Shares") pursuant to the Placing and Open offer by Protherics annouced 20 July 2004.
Exercise of Share Options
16 August 2004
Protherics PLC announces that following the exercise of share options, 5,000 new ordinary shares of 2p each were issued on the 13 Aug 2004, taking the total number of outstanding ordinary shares of 2p each to 228,528,174.
EGM Statement
12 August 2004
Protherics PLC, the international biopharmaceutical company, announces that at the extraordinary meeting held at 10:00 a.m. today, the resolution in connection with the company~s 10 million fundraising was passed.
Result of Open Offer
11 August 2004
Protherics PLC, the international biopharmaceutical company, announces that its open offer to Qualifying Shareholders closed at 3:00 p.m. today, 11 August 2004.
Results of AGM
23 July 2004
The Company is pleased to announce that at the Annual General Meeting which was held on the 23 July 2004
AGM Statement
22 July 2004
At the Annual General Meeting today, Stuart Wallis, Chairman, made the following statement to shareholders.
Protherics PLC announces 10 million fundraising
20 July 2004
Protherics PLC ("Protherics"), the international biopharmaceutical company, today announced that it proposes to raise approximately 10 million (before expenses) through the placing and open offer of up to 20,775,008 new ordinary shares. New ordinary shares are being offered at 48 pence per share, a discount of 6.8% to the closing price on 19 July 2004, on the basis of one new ordinary share for every existing ten ordinary shares held at the close of business on 16 July 2004.
Preliminary results for the 12 months eneded 31st March 2004
26 May 2004
Protherics PLC ("Protherics"), the international biopharmaceutical company, today announces its preliminary results for the twelve months to 31 March 2004
Protherics Announces Start of NQ02 Cancer Therapy Clinical Trial
20 May 2004
Protherics PLC ("Protherics"), the international biopharmacetical company, today announces the recruitment of the first patient in a Phase I study of its novel anti-cancer prodrug technology, NQO2, being undertaken by Cancer Research UK. Protherics also announces thay its primary application concerning this therapy has been allowed.
Directorate Change And Senior Management Appointment
22 April 2004
Protherics PLC today announces that Dr Tony Atkinson, previously Chief Scientific Officer (CSO) becomes a non-executive director of Protherics. Dr Atkinson, formerly Chief Executive of Enact Pharma PLC was appointed to the board of Protherics following the acquisition of Enact in June 2003. Protherics also announces that Dr Sally Waterman joins the company as Director of Research & Development.
Board Changes
16 April 2004
Protherics PLC announces the resignations of Dr Michael Peagram and Martin S Brown as non-executive Directors.
Abbott Announcement
08 April 2004
Protherics PLC acknowledges the recent announcement by Abbott Laboratories that it has received approval from the US Department of Agriculture to sell and distribute Enfer Scientific Limited~s bovine spongiform encephalopathy ("BSE") test in the US.
Protherics Appoints Code Securities As Financial Adviser And Joint Stockbroker And Confirms Panmure Gordon As Joint Stockbroker
03 March 2004
The Board of Protherics PLC is pleased to announce the appointment of Code Securities Limited as the Company~s financial adviser and joint stockbroker. The Company is also pleased to confirm the appointment of Panmure Gordon, a division of Lazard & Co., Limited, as joint stockbroker.
Appointment of Non-Executive Director
01 March 2004
Protherics PLC is pleased to announce the appointment of Dr John Brown as non-executive director, with immediate effect.
Protherics starts the next stage in Angiotensin Vaccine development
18 February 2004
Protherics PLC today announces the start of a new clinical programme to assess improved formulations of its Angiotensin Vaccine, incorporating third party proprietary vaccine adjuvants which have generated encouraging antibody titres in preclinical models.
Board Change
13 February 2004
Protherics PLC announces that Michael Gatenby resigned yesterday as a non-executive director of Protherics.
Appointment of Non-Executive Director
02 February 2004
Protherics PLC is pleased to announce the appointment of Garry Watts as a non-executive director, with immediate effect.
Protherics announces first named patient sales for Voraxaze in Europe
26 January 2004
Protherics PLC today announced its first named patient sales in Europe of Voraxaze, its treatment for patients at risk of kidney damage from methotrexate toxicity.
Dealings by Directors
22 January 2004
Protherics announces that on 21 January 2004, B M Riley exercised options over 72,011 ordinary shares of 2p each.
Protherics PLC announcement
15 January 2004
Protherics PLC acknowledges the recent announcement by Abbott Laboratories of a veterinary biological product license application to market and distribute Enfer Scientific Limited~s bovine spongiform encephalopathy (BSE) test in the US.
2008 News
2007 News Archive
2006 News Archive
2005 News Archive
2004 News Archive
2003 News Archive
2002 News Archive
2001 News Archive
2000 News Archive